Results 131 to 140 of about 242,314 (247)

Dynamics of natural killer cell function upon recurrent stimulation

Biotechnology Progress, EarlyView.
Weekly stimulation of peripheral blood‐derived NK cells with engineered K562 feeder cells resulted in two distinct growth phases, shifting around Day 21–26. Cells in growth phase 2 exhibited slower growth, reduced metabolic activity, and lower cytotoxicity than cells from growth phase 1, which has implications for NK cell biomanufacturing.
Jennifer One, Janani Narayan, Frank Cichocki, Wei‐Shou Hu, Samira M. Azarin   +4 more
wiley   +1 more source

Nano-curcumin enhances the sensitivity of tamoxifen-resistant breast cancer cells via the Cyclin D1-DILA1 axis and the PI3K/AKT/mTOR pathway downregulation. [PDF]

PLoS One
Givi T, Mohajerani F, Tehrankhah ZM, Karimi Taheri M, Amirahmadi M, Babashah S, Sadeghizadeh M.   +6 more
europepmc   +1 more source

Arabidopsis AUGMIN8 Contains Two Independent Microtubule Association Domains

Cytoskeleton, EarlyView.
ABSTRACT Plant cells create a plasma membrane‐associated network of microtubules that are nucleated by γ‐tubulin ring complexes primarily through microtubule‐dependent microtubule nucleation (MDMN). This dynamic array organizes into specific patterns in response to developmental and environmental cues to influence primary cell wall construction.
Naveen K. Chana, Timothy Cioffi, Sidney L. Shaw   +2 more
wiley   +1 more source

Mantle Cell Lymphoma Mimicking Parotid Neoplasm: A Rare Case Report. [PDF]

Iran J Otorhinolaryngol
Gupta T, Yadav S, Naseem AA, Singh SK, Rashmi R.   +4 more
europepmc   +1 more source

Longitudinal Tumor Size and Survival Modeling for Exposure–Response Analysis of Drugs with Frequent Dose Reductions: Dose Justification of Abemaciclib in Patients with Metastatic Breast Cancer

Clinical Pharmacology &Therapeutics, EarlyView.
Abemaciclib is an oral anticancer drug indicated for treatment of HR+ HER2‐ breast cancer. Dose modifications due to side effects are frequent, thus drug exposures change over time as a result of altering the dose or temporarily withholding abemaciclib treatment.
Emmanuel Chigutsa, Sonya C. Chapman, P. Kellie Turner   +2 more
wiley   +1 more source

CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction. [PDF]

Nat Commun
Luo L, Wang Y, Bui T, Jiang X, Chen MK, Rao X, Mohammadhosseinpour S, Li M, Kim S, Kim RY, Kamaliasl S, Ulizio CW, Tsavachidis S, Navarro-Yepes J, Kettner NM, Wingate H, Meric-Bernstam F, Hunt KK, Wang J, Faia K, Keyomarsi K.   +20 more
europepmc   +1 more source

Modulation of cyclin D1 and early growth response factor‐1 gene expression in interleukin‐1β‐treated rat smooth muscle cells by n‐6 and n‐3 polyunsaturated fatty acids [PDF]

, 2004
Souad Bousserouel, Michel Raymondjean, Arthur Brouillet, G. Béréziat, Marise Andréani   +4 more
openalex   +1 more source

The multiple hit model of infantile and epileptic spasms: The 2025 update

Epilepsia Open, EarlyView.
Abstract Objective Infantile and epileptic spasms syndrome (IESS) is a developmental and epileptic encephalopathy manifesting with epileptic spasms and poor neurodevelopmental outcomes. There is an urgent need for the development of more effective and tolerated therapies.
Aristea S. Galanopoulou, Wenzhu B. Mowrey, Wei Liu, Anna Maria Katsarou, Qianyun Li, Oleksii Shandra, Solomon L. Moshé   +6 more
wiley   +1 more source

Molecular and Immune Microenvironmental Changes Across Endometrial Lesions: A Comprehensive Immunohistochemical and Clinical Analysis of Progression From Benignity to Carcinoma. [PDF]

J Clin Med Res
Metreveli B, Gagua T, Gagua D, Kepuladze S, Burkadze G.   +4 more
europepmc   +1 more source

Cyclin D1 an early biomarker in oral carcinogenesis

, 2013
Ashwini Ramakrishna, Balasundari Shreedhar, TV Narayan, Leeky Mohanty, Sadhana Shenoy, Saleha Jamadar   +5 more
openalex   +2 more sources